XBiotech Inc

XBIT

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    85

Stocks News & Analysis

stocks

Investors again disappointed by ASX bank result

Solid result but valuation is stretched.
stocks

Big-four bank earnings surge but revenue growth elusive

Shares sell off after results.
stocks

This ASX supermarkets business is now underperforming its largest competitor

Competition restrains long-term margins.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,903.3031.200.35%
CAC 408,035.5259.400.74%
DAX 4024,350.37359.101.50%
Dow JONES (US)48,941.90557.37-1.13%
FTSE 10010,223.59140.34-1.35%
HKSE25,898.61197.27-0.76%
NASDAQ25,067.8046.64-0.19%
Nikkei 22559,513.12228.200.38%
NZX 50 Index13,035.7061.98-0.47%
S&P 5007,200.750.000.00%
S&P/ASX 2008,680.5038.800.45%
SSE Composite Index4,112.164.650.11%

Market Movers